DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQFINANCIAL SERVICESSHELL COMPANIES
Key Statistics
Market Cap
$258.79M
P/E Ratio
53.30
EPS
$0.20
Beta
—
52W High
$10.66
52W Low
$10.17
50-Day MA
$10.61
200-Day MA
$10.45
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company aimed at transforming the U.S. pharmaceutical industry by fostering strategic partnerships with innovative healthcare enterprises. With a commitment to enhancing domestic drug production and addressing critical supply chain vulnerabilities, DMAA seeks to ensure the availability of affordable medications for consumers. By leveraging cutting-edge technologies and promoting local manufacturing initiatives, DMAA is well-positioned to play a pivotal role in reshaping the landscape of pharmaceutical access in the United States.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.22 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $24.28M |
| Float | $27.90M |
| % Insiders | 23.57% |
| % Institutions | 98.23% |
Historical Volatility
HV 10-Day
1.37%
HV 20-Day
1.29%
HV 30-Day
1.23%
HV 60-Day
1.63%
HV Rank
5.2%
Volatility is currently expanding
More FINANCIAL SERVICES Stocks
Data last updated: 7/9/2026